Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Comput Urban Sci ; 3(1): 13, 2023.
Article in English | MEDLINE | ID: covidwho-2269161

ABSTRACT

The Community-Group-Buying Points (CGBPs) flourished during COVID-19, safeguarding the daily lives of community residents in community lockdowns, and continuing to serve as a popular daily shopping channel in the Post-Epidemic Era with its advantages of low price, convenience and neighborhood trust. These CGBPs are allocated on location preferences however spatial distribution is not equal. Therefore, in this study, we used point of interest (POI) data of 2,433 CGBPs to analyze spatial distribution, operation mode and accessibility of CGBPs in Xi'an city, China as well as proposed the location optimization model. The results showed that the CGBPs were spatially distributed as clusters at α = 0.01 (Moran's I = 0.44). The CGBPs operation mode was divided into preparation, marketing, transportation, and self-pickup. Further CGBPs were mainly operating in the form of joint ventures, and the relying targets presented the characteristic of 'convenience store-based and multi-type coexistence'. Influenced by urban planning, land use, and cultural relics protection regulations, they showed an elliptic distribution pattern with a small oblateness, and the density showed a low-high-low circular distribution pattern from the Palace of Tang Dynasty outwards. Furthermore, the number of communities, population density, GDP, and housing type were important driving factors of the spatial pattern of CGBPs. Finally, to maximize attendance, it was suggested to add 248 new CGBPs, retain 394 existing CGBPs, and replace the remaining CGBPs with farmers' markets, mobile vendors, and supermarkets. The findings of this study would be beneficial to CGB companies in increasing the efficiency of self-pick-up facilities, to city planners in improving urban community-life cycle planning, and to policymakers in formulating relevant policies to balance the interests of stakeholders: CGB enterprises, residents, and vendors.

2.
Pediatr Rheumatol Online J ; 20(1): 112, 2022 Dec 05.
Article in English | MEDLINE | ID: covidwho-2162383

ABSTRACT

BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a new syndrome with some clinical manifestations similar to Kawasaki disease (KD), which is difficult to distinguish. OBJECTIVE: The study aimed to characterize the demographic characteristics, clinical characteristics, laboratory features, cardiac complications, and treatment of MIS-C compared with KD. STUDY DESIGN: Studies were selected by searching the PubMed, EMBASE and so on before February 28, 2022. Statistical analyses were performed using Review Manager 5.4 software and STATA 14.0. RESULTS: Fourteen studies with 2928 participants were included. MIS-C patients tended to be older and there was no significant difference in the sex ratio. In terms of clinical characteristics, MIS-C patients were more frequently represented with respiratory, gastrointestinal symptoms and shock. At the same time, they had a lower incidence of conjunctivitis than KD patients. MIS-C patients had lower lymphocyte counts, platelet (PLT) counts, erythrocyte sedimentation rates (ESRs), alanine transaminase (ALT), and albumin levels and had higher levels of aspartate transaminase (AST), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), troponin, C-reactive protein (CRP), D-dimer, fibrinogen, ferritin, and creatinine. MIS-C patients had a higher incidence of left ventricle (LV) dysfunction, valvular regurgitation, pericardial effusion, myocarditis, and pericarditis. The incidence of coronary artery lesion (CAL) was lower in MIS-C patients [OR (95% CI): 0.52 (0.29, 0.93), p =0.03], while it was similar in the acute period. MIS-C patients had higher utilization of glucocorticoids (GCs) and lower utilization of intravenous immune globulin (IVIG). CONCLUSIONS: There were specific differences between MIS-C and KD, which might assist clinicians with the accurate recognition of MIS-C and further mechanistic research.


Subject(s)
COVID-19 , Mucocutaneous Lymph Node Syndrome , Child , Humans , Mucocutaneous Lymph Node Syndrome/drug therapy , Systemic Inflammatory Response Syndrome/epidemiology , Systemic Inflammatory Response Syndrome/etiology , Immunoglobulins, Intravenous/therapeutic use , C-Reactive Protein
SELECTION OF CITATIONS
SEARCH DETAIL